Emmett Till and Mamie Till-Mobley and Roberts Temple National Historic Site Act
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
91pct
113d open
vs 5,649 other S bills in the 118th — cohort avg 33d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (5)
2024 · fourth_quarter · Health Issues
Committee on Energy and Natural Resources Senate Subcommittee on National Parks. Hearings held. With printed Hearing: S.Hrg. 118-284.
Read twice and referred to the Committee on Energy and Natural Resources.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
H.R.8412 - Clinical Trial Modernization Act; a bill to modernize clinical trials and remove barriers for participation in clinical trials, and for other purposes. H.R. 2916/S. 1840 - Screening for Communities to Receive Early and Equitable Needed Services for Cancer Act of 2023; bill to amend the Public Health Service Act to reauthorize and improve the National Breast and Cervical Cancer Early Detection Program for fiscal years 2024 through 2028 H.R. 1092/S. 562 -Better Empowerment Now to Enhance Framework and Improve Treatments (BENEFIT) Act; requiring the Food and Drug Administration (FDA) to consider relevant patient-focused drug development data, such as data from patient preference studies and patient-reported outcome data, in the risk-benefit assessment framework used in the process for approving new drugs H.R. 3503/S. 1701 - NIH Clinical Trial Diversity Act; To direct the Secretary of Health and Human Services, acting through the Director of the National Institutes of Health, to take certain steps to increase clinical trial diversity, and for other purposes. H.R. 4363/S. 2213 - Comprehensive Cancer Survivorship Act; a bill to address the health of cancer survivors and unmet needs that survivors face through the entire continuum of care from diagnosis through active treatment and posttreatment, in order to improve survivorship, treatment, transition to recovery and beyond, quality of life and palliative care, and long-term health outcomes, including by developing a minimum standard of care for cancer survivorship, irrespective of the type of cancer, a survivor's background, or forthcoming survivorship needs, and for other purposes. S. 2243 - Palliative Care and Hospice Education and Training Act; a bill amend the Public Health Service Act to increase the number of permanent faculty in palliative care at accredited allopathic and osteopathic medical schools, nursing schools and other programs, including social work, physician assistant, and chaplaincy education programs, to promote education and research in palliative care and hospice, and to support the development of faculty careers in academic palliative and hospice care. S. 2140 - Patient Eligibility Restoration Act; a bill to amend the law relating to patent subject matter eligibility to establish that only specified subject matter (e.g., a natural process wholly independent of human activity) is ineligible for patenting. Policies related to sterile injectable medications shortages Policies related to administrative actions necessary in breast imaging and breast cancer diagnosis Policies related to genetic counseling and testing Policies to increase clinical trial diversity and access for underrepresented populations Policies related to cancer survivorship Policies related to PBM and drug cost transparency Comments related to draft Womens Preventive Services Initiative recommendations to Health Resources and Services Administration regarding screening for Breast Cancer Screening for Women at Average Risk and Patient Navigation Services for Breast and Cervical Cancer Screening Comments in response to Integrating Randomized Controlled Trials for Drug and Biological Products Into Routine Clinical Practice (FDA-2024-D-2052)
Client expense: $70,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE
2024 · fourth_quarter · Labor Issues/Antitrust/Workplace
H.R.20/S.567 - Richard L. Trumka Protecting the Right to Organize Act DOL Independent Contractor Rule NLRB Joint Employer Rule H.J. Res 98 - A resolution to repeal NLRB Joint Employer Rule H.J. Res 116 - A resolution to repeal the Independent Contractor Rule H.R.7194/S.3889 - Employee Rights Act H.R.1523/S.562 - Modern Worker Empowerment Act Package Delivery Parity Act Discussion Draft Legislative monitoring of activity related to the Railway Labor Act (RLA) OSHA Walkaround Rule Warehouse Workers Protection Act H.R.7784 - SALT Act
Client expense: $2,540,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Labor, Dept of (DOL), SENATE
2024 · third_quarter · Health Issues
H.R.8412 - Clinical Trial Modernization Act; a bill to modernize clinical trials and remove barriers for participation in clinical trials, and for other purposes. H.R. 2916/S. 1840 - Screening for Communities to Receive Early and Equitable Needed Services for Cancer Act of 2023; bill to amend the Public Health Service Act to reauthorize and improve the National Breast and Cervical Cancer Early Detection Program for fiscal years 2024 through 2028 H.R. 1092/S. 562 -Better Empowerment Now to Enhance Framework and Improve Treatments (BENEFIT) Act; requiring the Food and Drug Administration (FDA) to consider relevant patient-focused drug development data, such as data from patient preference studies and patient-reported outcome data, in the risk-benefit assessment framework used in the process for approving new drugs H.R. 3503/S. 1701 - NIH Clinical Trial Diversity Act; To direct the Secretary of Health and Human Services, acting through the Director of the National Institutes of Health, to take certain steps to increase clinical trial diversity, and for other purposes. H.R. 4363/S. 2213 - Comprehensive Cancer Survivorship Act; a bill to address the health of cancer survivors and unmet needs that survivors face through the entire continuum of care from diagnosis through active treatment and posttreatment, in order to improve survivorship, treatment, transition to recovery and beyond, quality of life and palliative care, and long-term health outcomes, including by developing a minimum standard of care for cancer survivorship, irrespective of the type of cancer, a survivor's background, or forthcoming survivorship needs, and for other purposes. S. 2243 - Palliative Care and Hospice Education and Training Act; a bill amend the Public Health Service Act to increase the number of permanent faculty in palliative care at accredited allopathic and osteopathic medical schools, nursing schools and other programs, including social work, physician assistant, and chaplaincy education programs, to promote education and research in palliative care and hospice, and to support the development of faculty careers in academic palliative and hospice care. S. 2140 - Patient Eligibility Restoration Act; a bill to amend the law relating to patent subject matter eligibility to establish that only specified subject matter (e.g., a natural process wholly independent of human activity) is ineligible for patenting. Comments in relation to the establishment of a Brain and Spine Metastasis Month Efforts related to breast screening recommendations by the United States Preventative Services Taskforce Policies related to ICD-10 codes for inflammatory breast cancer Policies related to sterile injectable medications shortages Policies related to administrative actions necessary in breast imaging and breast cancer diagnosis Policies related to genetic counseling and testing Policies to increase clinical trial diversity and access for underrepresented populations Policies related to cancer survivorship Policies related to PBM and drug cost transparency Policies related to reforms to the United States Preventative Services Taskforce Comments in response to Prohibition on Creditors and Consumer Reporting Agencies Concerning Medical Information (Regulation V) (CFPB-2024- 0023) Comments in response to the House Energy & Commerce Committee Framework for Discussion on Reforming the National Institutes of Health Comments in response to a Request for Information on 21st Century Cures Comments in response to Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies (FDA-2021D-0789)
Client expense: $100,000 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Consumer Financial Protection Bureau (CFPB), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE
2024 · third_quarter · Labor Issues/Antitrust/Workplace
H.R.20/S.567 - Richard L. Trumka Protecting the Right to Organize Act DOL Independent Contractor Rule NLRB Joint Employer Rule H.J. Res 98 - A resolution to repeal NLRB Joint Employer Rule H.J. Res 116 - A resolution to repeal the Independent Contractor Rule H.R.7194/S.3889 - Employee Rights Act H.R.1523/S.562 - Modern Worker Empowerment Act Package Delivery Parity Act Discussion Draft Legislative monitoring of activity related to the Railway Labor Act (RLA) OSHA Walkaround Rule Warehouse Workers Protection Act H.R.7784 - SALT Act
Client expense: $2,900,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Labor, Dept of (DOL), SENATE
2024 · second_quarter · Health Issues
H.R.8412 - Clinical Trial Modernization Act; a bill to modernize clinical trials and remove barriers for participation in clinical trials, and for other purposes. H.R. 2916/S. 1840 - Screening for Communities to Receive Early and Equitable Needed Services for Cancer Act of 2023; bill to amend the Public Health Service Act to reauthorize and improve the National Breast and Cervical Cancer Early Detection Program for fiscal years 2024 through 2028 H.R. 1092/S. 562 -Better Empowerment Now to Enhance Framework and Improve Treatments (BENEFIT) Act; requiring the Food and Drug Administration (FDA) to consider relevant patient-focused drug development data, such as data from patient preference studies and patient-reported outcome data, in the risk-benefit assessment framework used in the process for approving new drugs H.R. 3503/S. 1701 - NIH Clinical Trial Diversity Act; To direct the Secretary of Health and Human Services, acting through the Director of the National Institutes of Health, to take certain steps to increase clinical trial diversity, and for other purposes. H.R. 4363/S. 2213 - Comprehensive Cancer Survivorship Act; a bill to address the health of cancer survivors and unmet needs that survivors face through the entire continuum of care from diagnosis through active treatment and posttreatment, in order to improve survivorship, treatment, transition to recovery and beyond, quality of life and palliative care, and long-term health outcomes, including by developing a minimum standard of care for cancer survivorship, irrespective of the type of cancer, a survivor's background, or forthcoming survivorship needs, and for other purposes. S. 2243 - Palliative Care and Hospice Education and Training Act; a bill amend the Public Health Service Act to increase the number of permanent faculty in palliative care at accredited allopathic and osteopathic medical schools, nursing schools and other programs, including social work, physician assistant, and chaplaincy education programs, to promote education and research in palliative care and hospice, and to support the development of faculty careers in academic palliative and hospice care. S. 2140 - Patient Eligibility Restoration Act; a bill to amend the law relating to patent subject matter eligibility to establish that only specified subject matter (e.g., a natural process wholly independent of human activity) is ineligible for patenting. Comments in response to draft legislation titled the Drug Shortages Prevention and Mitigation Act Comments in relation to the establishment of a Brain and Spine Metastasis Month Comments in response to a request for information on appropriate use of artificial intelligence in healthcare Efforts related to breast screening recommendations by the United States Preventative Services Taskforce Policies related to ICD-10 codes for inflammatory breast cancer Policies related to sterile injectable medications shortages Policies related to administrative actions necessary in breast imaging and breast cancer diagnosis Policies related to genetic counseling and testing Policies to increase clinical trial diversity and access for underrepresented populations Policies related to cancer survivorship Policies related to PBM and drug cost transparency Policies related to reforms to the United States Preventative Services Taskforce Comments in response to Draft Guidance for Industry: Cancer Clinical Trial Eligibility Criteria: Performance Status (FDA-2024-D-1377); Cancer Clinical Trial Eligibility Criteria: Washout Periods and Concomitant Medications (FDA-2024-D1376); Cancer Clinical Trial Eligibility Criteria: Laboratory Values (FDA-2024-D-1402)
Client expense: $70,000 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE
2024 · second_quarter · Labor Issues/Antitrust/Workplace
H.R. 20/S. 567 - Richard L. Trumka Protecting the Right to Organize Act DOL Independent Contractor Rule NLRB Joint Employer Rule H.J. Res 98 - A resolution to repeal NLRB Joint Employer Rule H.J. Res 116 - A resolution to repeal the Independent Contractor Rule H.R. 7194/S. 3889 - Employee Rights Act H.R. 1523/S.562 - Modern Worker Empowerment Act Package Delivery Parity Act OSHA Walkaround Rule Warehouse Workers Protection Act H.R.7784 - SALT Act
Client expense: $2,620,000 · Firm income: Not reported
2024 · first_quarter · Health Issues
H.R. 2916/S. 1840 - Screening for Communities to Receive Early and Equitable Needed Services for Cancer Act of 2023; bill to amend the Public Health Service Act to reauthorize and improve the National Breast and Cervical Cancer Early Detection Program for fiscal years 2024 through 2028 H.R. 1092/S. 562 -Better Empowerment Now to Enhance Framework and Improve Treatments (BENEFIT) Act; requiring the Food and Drug Administration (FDA) to consider relevant patient-focused drug development data, such as data from patient preference studies and patient-reported outcome data, in the risk-benefit assessment framework used in the process for approving new drugs H.R. 1092/S. 562 -Better Empowerment Now to Enhance Framework and Improve Treatments (BENEFIT) Act; requiring the Food and Drug Administration (FDA) to consider relevant patient-focused drug development data, such as data from patient preference studies and patient-reported outcome data, in the risk-benefit assessment framework used in the process for approving new drugs H.R. 3503/S. 1701 - NIH Clinical Trial Diversity Act; To direct the Secretary of Health and Human Services, acting through the Director of the National Institutes of Health, to take certain steps to increase clinical trial diversity, and for other purposes. H.R. 4363/S. 2213 - Comprehensive Cancer Survivorship Act; a bill to address the health of cancer survivors and unmet needs that survivors face through the entire continuum of care from diagnosis through active treatment and posttreatment, in order to improve survivorship, treatment, transition to recovery and beyond, quality of life and palliative care, and long-term health outcomes, including by developing a minimum standard of care for cancer survivorship, irrespective of the type of cancer, a survivor's background, or forthcoming survivorship needs, and for other purposes. S. 2243 - Palliative Care and Hospice Education and Training Act; a bill amend the Public Health Service Act to increase the number of permanent faculty in palliative care at accredited allopathic and osteopathic medical schools, nursing schools and other programs, including social work, physician assistant, and chaplaincy education programs, to promote education and research in palliative care and hospice, and to support the development of faculty careers in academic palliative and hospice care. S. 2140 - Patient Eligibility Restoration Act; a bill to amend the law relating to patent subject matter eligibility to establish that only specified subject matter (e.g., a natural process wholly independent of human activity) is ineligible for patenting. Comments related to healthcare affordability Efforts related to breast screening recommendations by the United States Preventative Services Taskforce Efforts to preserve protections in the Affordable Care Act (ACA) for LGBTQ+ patients Policies related to ICD-10 codes for inflammatory breast cancer Policies related to sterile injectable medications shortages Policies related to administrative actions necessary in breast imaging and breast cancer diagnosis Policies related to genetic counseling and testing Policies to increase clinical trial diversity and access for underrepresented populations Policies related to cancer survivorship Policies related to PBM and drug cost transparency Policies related to reforms to the United States Preventative Services Taskforce
2024 · first_quarter · Labor Issues/Antitrust/Workplace
H.R. 20/S. 567 - Richard L. Trumka Protecting the Right to Organize Act DOL Independent Contractor Rule NLRB Joint Employer Rule H.J. Res 98 - A resolution to repeal NLRB Joint Employer Rule H.J. Res 116 - A resolution to repeal the Independent Contractor Rule H.R. 7194/S. 3889 - Employee Rights Act H.R. 1523/S.562 - Modern Worker Empowerment Act Package Delivery Parity Act OSHA Walkaround Rule Warehouse Workers Protection Act H.R.7784 - SALT Act
Client expense: $2,900,000 · Firm income: Not reported
2023 · fourth_quarter · Health Issues
H.R. 2916/S. 1840 - Screening for Communities to Receive Early and Equitable Needed Services for Cancer Act of 2023; bill to amend the Public Health Service Act to reauthorize and improve the National Breast and Cervical Cancer Early Detection Program for fiscal years 2024 through 2028 H.R. 1092/S. 562 -Better Empowerment Now to Enhance Framework and Improve Treatments (BENEFIT) Act; requiring the Food and Drug Administration (FDA) to consider relevant patient-focused drug development data, such as data from patient preference studies and patient-reported outcome data, in the risk-benefit assessment framework used in the process for approving new drugs H.R. 3503/S. 1701 - NIH Clinical Trial Diversity Act; To direct the Secretary of Health and Human Services, acting through the Director of the National Institutes of Health, to take certain steps to increase clinical trial diversity, and for other purposes. H.R. 4363/S. 2213 - Comprehensive Cancer Survivorship Act; a bill to address the health of cancer survivors and unmet needs that survivors face through the entire continuum of care from diagnosis through active treatment and posttreatment, in order to improve survivorship, treatment, transition to recovery and beyond, quality of life and palliative care, and long-term health outcomes, including by developing a minimum standard of care for cancer survivorship, irrespective of the type of cancer, a survivor's background, or forthcoming survivorship needs, and for other purposes. S. 2243 - Palliative Care and Hospice Education and Training Act; a bill amend the Public Health Service Act to increase the number of permanent faculty in palliative care at accredited allopathic and osteopathic medical schools, nursing schools and other programs, including social work, physician assistant, and chaplaincy education programs, to promote education and research in palliative care and hospice, and to support the development of faculty careers in academic palliative and hospice care. Efforts to reauthorize the Pandemic and All-Hazards Preparedness Act Efforts regarding the nomination and confirmation of new National Institutes of Health Director Comments in response to Medical Devices; Laboratory Developed Tests Proposed Rule Comments in response to modernizing the National Institutes of Health and Centers for Disease Control and Prevention Comments related to healthcare affordability Efforts related to breast screening recommendations by the United States Preventative Services Taskforce Policies related to sterile injectable medications shortages Policies related to administrative actions necessary in breast imaging and breast cancer diagnosis Policies related to the regulation of diagnostic devices Policies related to genetic counseling and testing Policies to increase clinical trial diversity and access for underrepresented populations Policies related to cancer survivorship Policies related to PBM and drug cost transparency Policies related to reforms to the United States Preventative Services Taskforce
2023 · fourth_quarter · Labor Issues/Antitrust/Workplace
H.R. 20/S. 567 - Richard L. Trumka Protecting the Right to Organize Act DOL Independent Contractor Rule NLRB Joint Employer Rule H.J. Res 98 - A resolution to repeal NLRB Joint Employer Rule H.R. 7194/S. 3889 - Employee Rights Act H.R. 1523/S.562 - Modern Worker Empowerment Act Package Delivery Parity Act
Client expense: $2,580,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Labor, Dept of (DOL), SENATE
2023 · third_quarter · Labor Issues/Antitrust/Workplace
H.R. 20/S. 567 - Richard L. Trumka Protecting the Right to Organize Act DOL Independent Contractor Rule DOL Joint Employer Rule H.R. 7194/S. 3889 - Employee Rights Act H.R. 1523/S.562 - Modern Worker Empowerment Act Package Delivery Parity Act
Client expense: $2,980,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Labor, Dept of (DOL), SENATE
2023 · third_quarter · Health Issues
H.R. 2916/S. 1840 - Screening for Communities to Receive Early and Equitable Needed Services for Cancer Act of 2023; bill to amend the Public Health Service Act to reauthorize and improve the National Breast and Cervical Cancer Early Detection Program for fiscal years 2024 through 2028 H.R. 1092/S. 562 -Better Empowerment Now to Enhance Framework and Improve Treatments (BENEFIT) Act; requiring the Food and Drug Administration (FDA) to consider relevant patient-focused drug development data, such as data from patient preference studies and patient-reported outcome data, in the risk-benefit assessment framework used in the process for approving new drugs H.R. 3503/S. 1701 - NIH Clinical Trial Diversity Act; To direct the Secretary of Health and Human Services, acting through the Director of the National Institutes of Health, to take certain steps to increase clinical trial diversity, and for other purposes. H.R. 4363/S. 2213 - Comprehensive Cancer Survivorship Act; a bill to address the health of cancer survivors and unmet needs that survivors face through the entire continuum of care from diagnosis through active treatment and posttreatment, in order to improve survivorship, treatment, transition to recovery and beyond, quality of life and palliative care, and long-term health outcomes, including by developing a minimum standard of care for cancer survivorship, irrespective of the type of cancer, a survivor's background, or forthcoming survivorship needs, and for other purposes. S. 2243 - Palliative Care and Hospice Education and Training Act; a bill amend the Public Health Service Act to increase the number of permanent faculty in palliative care at accredited allopathic and osteopathic medical schools, nursing schools and other programs, including social work, physician assistant, and chaplaincy education programs, to promote education and research in palliative care and hospice, and to support the development of faculty careers in academic palliative and hospice care. Efforts to reauthorize the Pandemic and All-Hazards Preparedness Act Efforts regarding the nomination and confirmation of new National Institutes of Health Director Comments regarding FDA Draft Guidance Decentralized Clinical Trials for Drugs, Biological Products, and Devices Comments in response to the discussion draft of the Stop Drug Shortages Act Efforts related to breast screening recommendations by the United States Preventative Services Taskforce Policies related to sterile injectable medications shortages Policies related to administrative actions necessary in breast imaging and breast cancer diagnosis Policies related to the regulation of diagnostic devices Policies related to genetic counseling and testing Policies to increase clinical trial diversity and access for underrepresented populations Policies related to cancer survivorship Policies related to PBM and drug cost transparency Policies related to reforms to the United States Preventative Services Taskforce
2023 · second_quarter · Health Issues
H.R. 2916/S. 1840 - Screening for Communities to Receive Early and Equitable Needed Services for Cancer Act of 2023; bill to amend the Public Health Service Act to reauthorize and improve the National Breast and Cervical Cancer Early Detection Program for fiscal years 2024 through 2028 H.R. 1092/S. 562 -Better Empowerment Now to Enhance Framework and Improve Treatments (BENEFIT) Act; requiring the Food and Drug Administration (FDA) to consider relevant patient-focused drug development data, such as data from patient preference studies and patient-reported outcome data, in the risk-benefit assessment framework used in the process for approving new drugs H.R. 3503/S. 1701 - NIH Clinical Trial Diversity Act; To direct the Secretary of Health and Human Services, acting through the Director of the National Institutes of Health, to take certain steps to increase clinical trial diversity, and for other purposes. H.R. 4363/S. 2213 - Comprehensive Cancer Survivorship Act; a bill to address the health of cancer survivors and unmet needs that survivors face through the entire continuum of care from diagnosis through active treatment and posttreatment, in order to improve survivorship, treatment, transition to recovery and beyond, quality of life and palliative care, and long-term health outcomes, including by developing a minimum standard of care for cancer survivorship, irrespective of the type of cancer, a survivor's background, or forthcoming survivorship needs, and for other purposes. S. 1339 - Pharmacy Benefit Manager Reform Act; bill establishes various requirements for pharmacy benefit managers (PBMs) with respect to services provided to health insurance plans Efforts to reintroduce legislation which requires the Department of Health and Human Services (HHS) to take a series of actions relating to palliative-care training known as the Palliative Care and Hospice Education and Training Act Comments regarding the nomination and confirmation of new National Institutes of Health Director Comments in response to a Congressional Request for Information regarding the role and mission of the Centers for Disease Control and Prevention Comments in response to draft recommendations on breast cancer screening release by the United States Preventative Services Taskforce Policies related to the implementation of the Breast Density and Mammography Reporting Act of 2017 and the 2023 Final Rule Amending Part 900 of the Mammography Quality Standards Act Policies related to the implementation of the National Cancer Institutes National Cancer Plan Policies related to sterile injectable medications shortages Policies related to administrative actions necessary in breast imaging and breast cancer diagnosis Policies related to the regulation of diagnostic devices Policies related to genetic counseling and testing Policies to increase clinical trial diversity and access for underrepresented populations Policies related to cancer survivorship Policies related to PBM and drug cost transparency Policies related to reforms to the United States Preventative Services Taskforce
2023 · second_quarter · Labor Issues/Antitrust/Workplace
H.R. 20/S. 567 - Richard L. Trumka Protecting the Right to Organize Act DOL Independent Contractor Rule DOL Joint Employer Rule H.R. 7194/S. 3889 - Employee Rights Act H.R. 1523/S.562 - Modern Worker Empowerment Act
Client expense: $3,100,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Labor, Dept of (DOL), SENATE
2023 · second_quarter · Government Issues
Lobbied in support of the Democracy in Design Act (H.R. 964/ S. 366). Lobbied in support of the Emmett Till and Mamie Till-Mobley and Roberts Temple National Historic Site Act (S. 562), the Historic Preservation Fund Reauthorization Act (H.R. 3350), and the Historic Tax Credit and Growth Opportunity Act (H.R. 1785/S. 639)
Client expense: $270,000 · Firm income: Not reported
Government targets: General Services Administration (GSA), HOUSE OF REPRESENTATIVES, SENATE, White House Office
2023 · second_quarter · Natural Resources
A bill to establish the Emmett Till and Mamie Till-Mobley and Roberts Temple National Historic Site in the State of Illinois (S. 562) Save Oak Flat from Foreign Mining Act (HR 1351) Springfield Race Riot National Monument Act (S. 384) The African American History Act (S. 233/H.R. 765) The National Council on African American History and Culture Act of 2023 (S. 215/H.R. 727) To amend the National Trails System Act to designate the Route 66 National Historic Trail, and for other purposes. (H.R. 4338) Lower Energy Costs Act (H.R. 1) Fiscal Responsibility Act (H.R. 3746/P.L. 118-5) Chaco Canyon Cultural Heritage Protection Act (H.R. 3062/S. 1404) Historic Preservation Fund Reauthorization (H.R. 3350) The School Infrastructure Modernization Act (S. 1523) A bill to provide that certain communications projects are not subject to requirements to prepare certain environmental or historical preservation reviews, and for other purposes. (H.R. 4141) Reconstruction Era National Historic Park (DRAFT)
Client expense: $32,556 · Firm income: Not reported
Government targets: Advisory Council on Historic Preservation (ACHP), Bureau of Land Management (BLM), HOUSE OF REPRESENTATIVES, Interior, Dept of (DOI), Natl Park Service (NPS), SENATE
2023 · second_quarter · Government Issues
Lobbied in support of the Democracy in Design Act (H.R. 964/ S. 366). Lobbied in support of the Emmett Till and Mamie Till-Mobley and Roberts Temple National Historic Site Act (S. 562).
Client expense: Not reported · Firm income: $60,000
Government targets: General Services Administration (GSA), HOUSE OF REPRESENTATIVES, SENATE, White House Office
2023 · first_quarter · Health Issues
Efforts to reintroduce legislation to reauthorize the National Breast and Cervical Cancer Early Detection Program H.R. 1092/S. 562 -Better Empowerment Now to Enhance Framework and Improve Treatments Act; requiring the Food and Drug Administration (FDA) to consider relevant patient-focused drug development data, such as data from patient preference studies and patient-reported outcome data, in the risk-benefit assessment framework used in the process for approving new drugs Policies related to the implementation of the Breast Density and Mammography Reporting Act of 2017 and the 2023 Final Rule Amending Part 900 of the Mammography Quality Standards Act Policies related to administrative actions necessary in breast imaging and breast cancer diagnosis Policies related to the regulation of diagnostic devices Policies related to genetic counseling and testing Policies to increase clinical trial diversity and access for underrepresented populations Policies related to cancer survivorship Policies related to PBM and drug cost transparency Policies related to reforms to the United States Preventative Services Taskforce
Client expense: $70,000 · Firm income: Not reported
2023 · first_quarter · Government Issues
Lobbied in support of the Democracy in Design Act (H.R. 964/ S. 366). Lobbied in support of the Emmett Till and Mamie Till-Mobley and Roberts Temple National Historic Site Act (S. 562).
Client expense: Not reported · Firm income: $60,000
Government targets: General Services Administration (GSA), HOUSE OF REPRESENTATIVES, SENATE, White House Office
2023 · first_quarter · Government Issues
Lobbied in support of the Democracy in Design Act (H.R. 964/ S. 366). Lobbied in support of the Emmett Till and Mamie Till-Mobley and Roberts Temple National Historic Site Act (S. 562).
Client expense: $310,000 · Firm income: Not reported
Government targets: General Services Administration (GSA), HOUSE OF REPRESENTATIVES, SENATE, White House Office
2023 · first_quarter · Natural Resources
A bill to establish the Emmett Till and Mamie Till-Mobley and Roberts Temple National Historic Site in the State of Illinois (S. 562) Save Oak Flat from Foreign Mining Act (HR 1351) Springfield Race Riot National Monument Act (S. 384) The African American History Act (S. 233/H.R. 765) The National Council on African American History and Culture Act of 2023 (S. 215/H.R. 727) To amend the National Trails System Act to designate the Route 66 National Historic Trail, and for other purposes. (DRAFT) Lower Energy Costs Act (H.R. 1) Reconstruction Era National Historic Park (DRAFT)
Client expense: $43,170 · Firm income: Not reported
Government targets: Advisory Council on Historic Preservation (ACHP), Bureau of Land Management (BLM), HOUSE OF REPRESENTATIVES, Interior, Dept of (DOI), Natl Park Service (NPS), SENATE
| Republican |
| MS |
Government targets: HOUSE OF REPRESENTATIVES, Labor, Dept of (DOL), SENATE
Client expense: $70,000 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE
Government targets: HOUSE OF REPRESENTATIVES, Labor, Dept of (DOL), SENATE
Client expense: $60,000 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE
Client expense: $60,000 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE
Client expense: $110,000 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE
Government targets: Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE